Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Dundee |
---|---|
Information provided by: | University of Dundee |
ClinicalTrials.gov Identifier: | NCT00679250 |
Allergic rhinitis is a common condition characterize by inflammation of the upper airways. Third generation antihistamines have been demonstrated effective in the treatment of this condition. Allergen challenge can be use to assess the effects of drugs in allergic rhinitis, adenosine monophosphate may also be used as a means to investigate these effects but as yet its effects have yet to be compared to allergen challenge. We intend to compare the effects of levocetirizine at a single dose of 5mg on allergen and AMP challenge compared to placebo in a double blind cross-over study. The study will include 20 patients with allergic rhinitis. Each patient will have allergen and AMP challenge on placebo and active treatment. The primary outcome variable will be the change in concentration of AMP/Allergen required to produce a 20% drop in nasal flow as manifest by peak nasal inspiratory flow. A 1 doubling dose change in concentration of challenge medium to cause a 20% drop in nasal flow will be deemed significant. We will also measure time to recovery after both challenges. AMP challenge is a safe alternative to allergen challenge and does not have the risk of anaphylaxis.
Condition | Intervention | Phase |
---|---|---|
Allergic Rhinitis |
Drug: levocetirizine Drug: placebo to levocetirizine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis |
Enrollment: | 25 |
Study Start Date: | November 2005 |
Study Completion Date: | December 2006 |
Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Levocetirizine: Experimental
Active drug
|
Drug: levocetirizine
5 mg once nightly before visit
|
placebo: Placebo Comparator
placebo to levocetirizine
|
Drug: placebo to levocetirizine
1 tablet once nightly before visit
|
Ages Eligible for Study: | 16 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United Kingdom, Angus | |
Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee) | |
Dundee, Angus, United Kingdom, DD1 9SY | |
United Kingdom, Perthshire | |
Perth Royal Infirmary | |
Perth, Perthshire, United Kingdom, PH1 1NX |
Principal Investigator: | Arun Nair, MRCP | University of Dundee |
Responsible Party: | University of Dundee ( Dr Arun Nair ) |
Study ID Numbers: | GRAY09, 2004-000683-27 |
Study First Received: | May 14, 2008 |
Last Updated: | May 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00679250 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
allergic rhinitis levocetirizine nasal provocation testing nasal allergen challenge nasal adenosine monophosphate challenge |
Otorhinolaryngologic Diseases Respiratory Tract Infections Respiratory Tract Diseases Levocetirizine Histamine phosphate |
Rhinitis Cetirizine Adenosine Histamine |
Neurotransmitter Agents Vasodilator Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Histamine Agents Anti-Allergic Agents Cardiovascular Agents Nose Diseases Pharmacologic Actions |
Histamine Antagonists Sensory System Agents Therapeutic Uses Histamine H1 Antagonists Analgesics Peripheral Nervous System Agents Anti-Arrhythmia Agents Histamine H1 Antagonists, Non-Sedating Central Nervous System Agents |